It has been demonstrated recently that BRAFi treatment can alter NKG2D ligand expression in BRAFV600E‐mutated melanoma cell lines.50 In agreement with this study, we also detected lower mRNA levels of the NKG2D ligands in BRAFi‐treated tumors which could facilitate the escape of tumor cells to NK cell‐mediated killing. The gene discussed is KLRK1; the disease is neoplasm.